What are the criteria for considering discontinuation of eculizumab?

Aetna considers eculizumab, or its biosimilar, medically necessary for any of the following indications when criteria are met: As anti-C5 therapy like eculizumab is the only treatment for patients with aHUS, optimizing treatment is indispensable. The drug label states that a trough ... Soliris was approved by the U.S. Food and Drug Administration in 2019 for the treatment of adults with NMOSD who are positive for anti-AQP4 antibodies. The ... Paroxysmal Nocturnal Hemoglobinuria (PNH). SOLIRIS is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce ... Eculizumab is a humanized monoclonal antibody directed against C5 of the complement cascade and thereby inhibits the formation of C5a and C5b-9 membrane attack ... Access to Eculizumab for patients with aHUS. NHS England published NICE guidance for the use of Eculizumab for treating in aHUS in January 2015. This article contains billing and coding guidelines that complement the Local Coverage Determination (LCD) Drugs and Biologicals, Coverage of, for Label and ... 600mg weekly for the first 4 weeks, followed by 900mg for the fifth dose 1 week later, then 900mg every 2 weeks thereafter. Eculizumab is an oral medication designed to block the action of endothelin, a natural substance in the body that narrows blood vessels. By inhibiting ... Sep 19, 2021 ... Eculizumab is an anti-C5 humanized monoclonal antibody that binds to C5, preventing its cleavage into C5a and C5b.